HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Sionna Therapeutics, Inc.

Contributing Author

Recent Articles by Sionna Therapeutics, Inc.

4 hours
Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium SION GlobeNewswire
Mar-02
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results SION -7.17% GlobeNewswire
Feb-23
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences SION GlobeNewswire
Feb-04
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 SION -7.12% GlobeNewswire
Jan-05
Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference SION GlobeNewswire
Nov-24
Sionna Therapeutics to Participate in Upcoming December Investor Conferences SION GlobeNewswire
Nov-05
Sionna Therapeutics Reports Third Quarter 2025 Financial Results SION GlobeNewswire
Nov-04
Sionna Therapeutics to Participate in Upcoming November Investor Conferences SION GlobeNewswire
Oct-24
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference SION GlobeNewswire
Oct-21
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis SION +31.99% GlobeNewswire
Oct-01
Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference SION GlobeNewswire
Sep-08
Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer SION -9.92% GlobeNewswire
Aug-27
Sionna Therapeutics to Participate in Upcoming September Investor Conferences SION GlobeNewswire
Aug-25
Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis SION GlobeNewswire
Aug-11
Sionna Therapeutics Reports Second Quarter 2025 Financial Results SION +13.36% GlobeNewswire
Jun-06
Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model SION +7.42% GlobeNewswire
Jun-04
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis SION +9.12% GlobeNewswire
Jun-03
Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference SION GlobeNewswire
May-22
Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference SION GlobeNewswire
May-12
Sionna Therapeutics Reports First Quarter 2025 Financial Results SION GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)